Formulations for reducing neuronal degeneration

Abstract

Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer's disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).

1 . A method for treating a neurodegenerative disorder in a mammal, the method comprising administering to the mammal an amount of a formulation effective to reduce a level of reactive oxygen species (ROS) in an in vitro neural cell culture, wherein the formulation comprises, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms. 
     
     
         2 . The method of  claim 1 , wherein the formulation comprises folate, vitamin E, ALCAR, NAC, and SAM. 
     
     
         3 . The method of  claim 1 , wherein the mammal suffers from a neurodegenerative disorder selected from the group consisting of Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis (ALS). 
     
     
         4 . The method of  claim 1 , wherein the mammal is a human. 
     
     
         5 . The method of  claim 1 , wherein a level of reactive oxygen species (ROS) in the mammal is reduced compared to a reference. 
     
     
         6 . A composition comprising, folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition reduces a level of reactive oxygen species (ROS) in an in vitro neural cell culture. 
     
     
         7 . The composition of  claim 6 , wherein the composition comprises folate, vitamin E, ALCAR, NAC, and SAM. 
     
     
         8 - 25 . (canceled) 
     
     
         26 . The composition of  claim 6 , wherein the unit dose comprises about 200-2000 μg folate. 
     
     
         27 . The composition of  claim 6 , wherein the unit dose comprises about 50-3000 I.U. vitamin E. 
     
     
         28 . The composition of  claim 6 , wherein the unit dose comprises about 200-4000 mg ALCAR. 
     
     
         29 . The composition of  claim 6 , wherein the unit dose comprises about 200-2000 mg NAC. 
     
     
         30 . The composition of  claim 6 , wherein the unit dose comprises about 400-2000 mg SAM. 
     
     
         31 . The composition of  claim 6 , wherein the unit dose comprises about 20-500 mg DZA. 
     
     
         32 . The composition of  claim 7 , wherein the unit dose comprises about 200-2000 μg folate, about 50-3000 I.U. vitamin E, about 200-4000 mg ALCAR, about 200-2000 mg NAC, and about 400-2000 mg SAM. 
     
     
         33 . The composition of  claim 7 , wherein the unit dose comprises about 400-1500 μg folate, about 50 I.U. vitamin E, about 500-3000 mg ALCAR, about 500-1500 mg NAC, and about 400-1500 mg SAM. 
     
     
         34 . The composition of  claim 7 , wherein the unit dose of the composition comprises about 200-2000 μg folate, about 200-4000 mg ALCAR, about 400-2000 mg SAM, and about 200-2000 mg NAC. 
     
     
         35 . The composition of  claim 7 , wherein the unit dose of the composition comprises about 400-1500 μg folate, about 500-3000 mg ALCAR, about 400-1500 mg SAM, and about 500-1500 mg NAC. 
     
     
         36 . A composition comprising folate, vitamin E, acetyl-L-carnitine (ALCAR), and at least two of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM), in combination or in individual dosage forms, wherein a unit dose of the composition improves memory in a subject. 
     
     
         37 . A method of improving memory in a subject, comprising administering a composition of any one of  claim 6 ,  7 , or  26 - 35  to the subject, such that memory is improved.